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Abstract  
 
This study was conducted during the period from February 2004 to July 
2004; with the objective of measuring the levels of estrogen (E2), 
carcinoembryonic Antigen (CEA) and cancer antigen of breast (CA-15.3) 
so as to facilitate the early diagnosis of breast cancer and to determine the 
involvement of these parameters as risk factors for breast cancer.   
          Ninety blood samples were collected from Sudanese females, 
divided into two groups; control group and patients groups. The patients 
group was sixty Sudanese females visiting the Radio Isotope Center, 
Khartoum (RICK) and they were confirmed as breast cancer patients by 
histopathology.           
          The levels of the above mentioned parameters were determined by 
using radioimmunoassay technique.  
          The results showed that, no significant (p=0.05) difference between 
the levels of the estrogen in patients compared to the control, on the other 
hand there was non-significant (p>0.05) elevation in CEA levels in the 
patients with breast cancer compared to the control. The level of CA15.3 
was significantly (p<0.0001) higher in the breast cancer patients 
compared to the control.  
 
 
 
 
 
 
 
 
  
 
  اﻟﺨﻼﺻﺔ
  
ﻗﺔ ﺑﻴﻦ  ﺑﻬﺪف اﻟﺘﺄآﺪ ﻣﻦ اﻟﻌﻼ4002 اﻟﻰ ﻳﻮﻧﻴﻮ 4002 ﻓﻲ اﻟﻔﺘﺮﻩ ﻣﻦ ﻓﺒﺮاﻳﺮ أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ
هﺮﻣﻮن اﻻﺳﺘﺮوﺟﻴﻦ واﻟﻤﺴﺘﻀﺪ اﻟﺠﻨﻴﻨﻲ وﻣﺴﺘﻀﺪ ﺳﺮﻃﺎن اﻟﺜﺪي واﺣﺘﻤﺎل اﻹﺻﺎﺑﺔ ﺑﺴﺮﻃﺎن 
  .اﻟﺜﺪي
ﺗﻢ ﺟﻤﻊ ﻋﻴﻨﺎت دم ﻣﻦ ﺳﺘﻴﻦ ﻣﺮﻳﻀﺔ ﺑﺴﺮﻃﺎن اﻟﺜﺪي  ﻣﻦ ﻣﺮآﺰ ﻋﻼج اﻷورام ﺑﺎﻟﺨﺮﻃﻮم 
، وﺟﻤﻌﺖ ﺛﻼﺛﻮن ﻋﻴﻨﺔ دم أﺧﺮى ﻣﻦ ﻧﺴﺎء ﻏﻴﺮ ﻣﺼﺎﺑﺎت ﻻﺳﺘﺨﺪاﻣﻬﺎ  ( ﻣﺴﺘﺸﻔﻰ اﻟﺬرة)
  .آﻤﺠﻤﻮﻋﺔ ﺗﺤﻜﻢ
ﺑﻤﻌﻤﻞ هﻴﺌﻪ اﻟﻄﺎﻗﺔ ( yassaonummioidaR)اﻟﻌﻴﻨﺎت ﺗﻢ ﺗﺤﻠﻴﻠﻬﺎ ﺑﺘﻘﻨﻴﺔ اﻟﻤﻨﺎﻋﺔ اﻹﺷﻌﺎﻋﻴﺔ آﻞ 
  .اﻟﺬرﻳﺔ
ﺑﻌﺪ إﺟﺮاء اﻟﺘﺤﺎﻟﻴﻞ اﻹﺣﺼﺎﺋﻴﺔ ﻋﻠﻰ اﻟﻨﺘﺎﺋﺞ أﺗﻀﺢ أﻧﻪ ﻻ ﺗﻮﺟﺪ ﻓﺮوﻗﺎت ﻣﻌﻨﻮﻳﺔ ﻓﻰ آﻞ ﻣﻦ  
ﺑﻴﻦ اﻟﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت ﺑﺴﺮﻃﺎن ( 50.0>p) اﻟﺠﻨﻴﻨﻲﺪواﻟﻤﺴﺘﻀ (50.0=p)هﺮﻣﻮن اﻻﺳﺘﺮوﺟﻴﻦ 
ﻣﺠﻤﻮﻋﺔ اﻟﺘﺤﻜﻢ، وﻣﻦ ﻧﺎﺣﻴﺔ أﺧﺮى أوﺿﺤﺖ هﺬة اﻟﺪراﺳﺔ أن هﻨﺎك زﻳﺎدة ﻣﺆﺛﺮة ﻓﻰ اﻟﺜﺪى و
ﺑﺴﺮﻃﺎن اﻟﺜﺪى ﺑﺎﻟﻤﻘﺎرﻧﺔ ﻣﻊ ﻣﺠﻤﻮﻋﺔ اﻟﺘﺤﻜﻢ  ﻣﺴﺘﻀﺪ ﺳﺮﻃﺎن اﻟﺜﺪي ﻓﻰ اﻟﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت
  (.1000.0<p)
وﻣﻦ هﺬا ﻧﺨﻠﺺ أن هﺬﻩ اﻟﺪراﺳﺔ أﻋﻄﺖ ﻣﺆﺷﺮا ﺟﻴﺪا ﻻﺳﺘﺨﺪام ﺑﻌﺾ ﻣﻮﺳﻤﺎت اﻷورام ﻓﻲ 
      .     ﻟﻤﺒﻜﺮ ، وﻣﻦ أﻗﻮى هﺬﻩ اﻟﻤﻮﺳﻤﺎت ﻣﺴﺘﻀﺪ ﺳﺮﻃﺎن اﻟﺜﺪياﻟﻤﺴﺎﻋﺪة ﻓﻲ اﻟﺘﺸﺨﻴﺺ ا
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INTRODUCTION 
 
Breast cancer is ranked as the second common cancer around the 
world. It is most common in females, though males can develop breast 
cancer as well; it is believed to be the second cause of death (US 
mortality public, 2004). The relationship between developing breast 
cancer and some parameters has been stated; amongst them were estrogen 
(E2), carcinoembryonic antigen (CEA) and cancer antigen of breast (CA 
15.3) (Lupulescu, 1995; Fletcher, 1996; Pamies, et al. 1996). 
          CEA is one of the first tumor markers to be identified and 
characterized and has been evaluated in a wide range of malignancies, 
including breast cancer (Sikorska, et al. 1988). The availability of the CA 
15.3 tumor marker encouraged its use as a tumour marker for breast 
cancer favorably for its high sensitivity in both early and advanced 
diseases.  Nevertheless, CEA is still a widely used test for monitoring 
breast cancer patients (Van Dalen, et al. 1996).   
          Estrogen is important for normal sexual development and is 
essential for the normal functioning of the female organs needed for 
childbearing such as the ovaries and uterus (Massaro, et al. 2004). 
Estrogen as risk factor is strongly suggested to have role in the 
development of breast cancer (Toniolo, et al. 1995). However, some 
studies reported that no relationship between the estrogen concentrations 
and the breast cancer (Sturgeon, et al. 2004).   
 
 
 
 
Objectives of the study 
  
This study was conducted to satisfy the following objectives: 
  1- The main objective of this study is to determine the levels of   
             estrogen E2, carcinoembryonic antigen CEA and cancer antigen 
of               
             breast CA-15.3 in breast cancer patients compared to the control. 
         2- The use of these parameters in the early diagnosis of breast 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
  
 
LITERATURE REVIEW 
 
1.1 Cell cycle  
                Cells engaged in proliferation pass through four phases which 
together constitute the cell cycle (Fig. 1). In gap-1 (G1) preparation is 
made to enter DNA synthesis. In S, DNA synthesis occurs. In G2 the cell 
assembles the machinery for distributing the newly replicated 
chromosomes equally to the two daughter cells which are generated in M, 
mitosis. A great many cells in normal tissues, however, are in none of 
these phases. Some are in a non-proliferating state called G0, or growth 
arrest, from which they can be activated to enter the cell cycle in G1. 
Others can no longer the cycle; they are committed to terminal 
differentiation and death. The process whereby cells stimulated to move 
from one phase of the cycle to the next is called cell cycle control. 
Incontrast, the control of entry to the proliferative state from G0 is called 
growth control (Andrew and Tim, 1993). 
 
1.1.1 Cell growth control 
         Cells move from the quiescent G0 state into G1 in response to 
specific stimuli. The best known of these are locally active peptides and 
lipoproteins called growth factors. Some growth factors act on wide 
spectrum of cell types; examples include platelet derived growth factor 
(PDGF), the somatomedins or insulin-like growth factors (IGFs) and the 
acidic and basic fibroblast growth factors (a-and b-FGF) which, despite 
their name, stimulate proliferation in many cells in addition to fibroblasts.    
 
 
  
 
 
 
 
Fig. 1: Schematic Drawing of the Cell Cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Epidermal growth factors (EGF) acts predominantly on epithelial 
cells. Tumor-derived growth factor alpha (TGFα) is a closely related 
peptide. Some growth factors have the opposite effect and inhibit 
proliferation of certain target cells (e.g. Transforming Growth Factor β, 
 
  
TGFβ). Many familiar hormones also exert positive or negative growth 
factor activity on their target cells (e.g. thyroid hormones on thyroid 
epithelium, progesterone on mammary epithelium). Growth factors 
influence their target cells by binding to the specific receptors. Sometimes 
they stimulate their target cells to synthesize and display receptors to 
other factors, so rendering the cell capable of response to proliferative 
stimuli to which it was previously inert (Gary and Arthur, 2004). 
 
1.2 Tumors  
          Tumors are an abnormal mass of tissue, the growth of which 
exceeds and is uncoordinated with that of the normal tissues, and persists 
in the same excessive manner after cessation of the stimuli which evoked 
the change (Pamies, et al. 1996) 
          Tumors are divided into two classes, benign and malignant; the 
critical distinction between them is their mode of growth. Benign tumours 
grow by expansion, compressing or displacing surrounding normal tissue, 
but malignant tumors grow by local infiltration, destroying the tissue 
through which they invade. Benign tumors grow at the site of origin only, 
but malignant tumors may spread to distant sites, by the blood stream, in 
the lymphatics, or across tissue spaces such as the peritoneal or pleural 
cavities, or the cerebrospinal fluid space (Philip and Harris, 2001). This 
extremely important and dangerous property of malignant tumours called 
metastasis, and the secondary tumors which grow at the distant sites are 
metastases. Malignant tumors also tend to have a faster rate of growth 
than benign tumors. As a result, benign and malignant tumors have 
different clinical effects. By virtue of their position, benign tumors may 
cause symptoms by compression of adjacent structures, or in certain 
specific circumstances they may secrete hormones which contribute to the 
manifestations of disease. Incontrast, malignant tumors always have the 
  
potential to cause death as a result of their aggressive growth behavior. 
Cancer is the common term in use and is defined as malignant tumor 
which is invasive and metastatic (Daugaard, 2001). 
 
1.3 Breast cancer 
          With the possible exception of skin, breast cancer is the most 
common human female cancers throughout the world, although men can 
also develop this disease. It is more than 100 times more common in 
women than in men. During the mid-1980s mortality from cancer of the 
breast overtook that of every other female cancer to become the 
commonest cause of cancer death (Key, 2001). Breast cancer can develop 
at any age, but the risk of developing it increases as women get older. It is 
the second leading cause of cancer death for American women. While 5% 
to 10% of breast cancers are related to an inherited defect in one of two 
genes (BRCA1, BRCA2), the majority of cases develop for reasons we 
do not yet understand (Tonin, 2000). As a general rule, those at higher 
risk of developing breast cancer include women whose close relatives 
have had the disease (Colditz et al. 1996), women who have not had 
children and women who had their first child after the age of 30 (Kelsey 
and Horn-Ross, 1993). 
          Breast cancer divided into three stages, reflecting the extent to 
which the cancer has spread in the body.  
1.3.1 Early stage 
           Breast cancer is usually confined to the ducts (which transport 
milk to the nipple during lactation or to the lobules (small areas of tissue 
where milk is produced in the breast) and is known as noninvasive 
cancer. If the cancer is confined to the ducts, it is called ductal carcinoma 
in situ (DCIS) and if it is confined to the lobules, it is called lobular 
carcinoma in situ (LCIS). At this stage, the cancer cannot be felt as a 
  
lump in the breast, but DCIS can sometimes be detected by 
mammography (Singletary, 2002). 
 
1.3.2 Invasive stage  
          It is characterized by a spread of the cancer beyond the ducts or 
lobules and into the surrounding areas of breast tissue. At this stage, the 
cancer may be detected through a breast self-exam, by a clinical breast 
examination performed by health care professional, or by mammography 
(Singletary, 2002).  
 
1.3.3 Metastatic stage  
          There is a huge spread to other areas of the body, including nearby 
lymph nodes (Singletary, 2002).  
 
1.3.4 Risk factors 
          A risk factor is anything that increases your chance of getting a 
disease, such as cancer. Different cancers have different risk factors. For 
example, exposing skin to strong sunlight is a risk factor for skin cancer. 
Smoking is a risk factor for cancers of the lung, mouth, larynx, bladder, 
kidney, and several other organs, but having a risk factor, or even several, 
does not mean that you will get the disease. Some women who have one 
or more breast cancer risk factors never develop the disease, while most 
women with breast cancer have no apparent risk factors. Even when a 
woman with breast cancer has a risk factor, there is no way to prove that 
it actually caused her cancer (Susan, 2005).  
          There are different kinds of risk factors. Some factors, like a 
person's age or race, can't be changed. Others are linked to cancer-causing 
factors in the environment. Still others are related to personal choices 
such as smoking, drinking, and diet. Some factors influence risk more 
than others, and your risk for breast cancer can change over time, due to 
  
factors such as aging or lifestyle (Susan, 2005). The following are some 
risk factors: 
 
Gender: simply being a woman is the main risk factor for developing 
breast cancer. Because women have many more breast cells than men do 
and perhaps because their breast cells are constantly exposed to the 
growth-promoting effects of female hormones, breast cancer is much 
more common in women. Men can develop breast cancer, but this disease 
is about 100 times more common among women than men (Kelsey and 
Horn-Ross, 1993).  
  
Aging: Age is the most important risk factor for women, the risk of 
developing breast cancer increases as you get older. About 18% of breast 
cancer diagnoses are among women in their 40's, while about 77% of 
women with breast cancer are older than 50 when they are diagnosed 
(Kelsey and Horn-Ross, 1993).  
 
Cancer genes: certain changes in DNA can cause normal breast cells to 
become cancerous. Some genes contain instructions for controlling when 
our cells grow, divide, and die. Certain genes that promote cell division 
are called oncogenes (such as BRCA1, BRCA2). Others that slow down 
cell division, or cause cells to die at the right time, are called tumor 
suppressor genes (p53). It is known that cancers can be caused by DNA 
mutations (changes) that "turn on" oncogenes or "turn off" tumor 
suppressor genes.  
         The (p53) gene is a tumor suppressor gene. When it is mutated, it no 
longer functions to suppress abnormal growth and cancer is more likely 
to develop. Certain inherited DNA changes can cause a high risk for 
developing cancer in people who carry these changes and are responsible 
for the cancers that run in some families.  
  
          Most DNA mutations related to breast cancer, however, occur in 
single breast cells during a woman's life rather than having been 
inherited. Acquired mutations of oncogenes and/or tumor suppressor 
genes may result from radiation or cancer-causing chemicals. So far, 
however, studies have not been able to identify any chemical in the 
environment or in our diets that is likely to cause these mutations, or a 
subsequent breast cancer. The cause of most acquired mutations remains 
unknown (Tonin, 2000).  Recent studies have shown that about 10% of 
breast cancer cases are hereditary as a result of gene changes (mutations). 
The most common gene changes are those of the BRCA1 and BRCA2 
genes (Tonin, 2000). Normally, these genes help to prevent cancer by 
making proteins that keep cells from growing abnormally. However, if 
you have inherited changed gene from either parent, you are at increased 
risk for breast cancer.  
 
Family history of breast cancer: breast cancer risk is higher among 
women whose close blood relatives have this disease. Having one first-
degree relative with breast cancer approximately doubles a woman's risk, 
and having two first-degree relatives increases her risk 5-fold. Although 
the exact risk is not known, women with a family history of breast cancer 
in a father or brother also have an increased risk of breast cancer (Colditz, 
et al. 1996). Altogether, about 20% to 30% of women with breast cancer 
have a family member with this disease. 
 
Race: white women are slightly more likely to develop breast cancer than 
are African-American women. But African-American women are more 
likely to die of this cancer because their cancers are often diagnosed later 
and at an advanced stage when they are harder to treat and cure. There is 
also some question about whether African-American women have more 
  
aggressive tumors. Asian, Hispanic, and Native American women have a 
lower risk of developing breast cancer (National Academy of Sciences, 
2005).  
 
Previous breast biopsy: women whose earlier breast biopsies detected 
proliferative breast disease without a typical or usual hyperplasia have a 
slightly higher risk of breast cancer (1.5 to 2 times greater than other 
women). Having a previous biopsy result of a typical hyperplasia 
increases a woman's breast cancer risk by 4 to 5 times. Having a biopsy 
specimen diagnosed as fibrocystic changes without proliferative breast 
disease does not affect breast cancer risk (Morris, 2003). 
 
Previous breast radiation: women who as children or young adults have 
had radiation therapy to the chest area as treatment for another cancer 
(such as Hodgkin's disease or non-Hodgkin's lymphoma) have a 
significantly increased risk for breast cancer. Some reports found the risk 
to be 12 times normal. This varies with the age of the patient at the time 
of the radiation. Younger patients have a higher risk. If chemotherapy 
was also given, the risk is lowered because the chemotherapy often stops 
ovarian hormone production (John and Kelsey, 1993).  
 
Menstrual periods: women who started menstruating at an early age 
(before age 12) or who went through menopause at a late age (after age 
55) have a slightly higher risk of breast cancer (Colditz, et al. 1995). 
 
Chemical carcinogenesis: there are some chemicals that play role in the 
breast cancer (Nicola, et al. 2003). 
 
 Diethylstilbestrol (DES) Therapy: in the 1940’s through the 1960’s some 
pregnant women were given diethylstilbestrol because it was thought to 
  
lower their chances of losing the baby.  Some studies have shown that 
these women have a slightly increased risk of developing breast cancer 
(Calle, et al. 1996). 
 
Oral contraceptive: it is still not certain what part of oral contraceptives 
might play in breast cancer risk. Studies have suggested that women 
using oral contraceptives have a slightly greater risk of breast cancer than 
women who have never used them. Women who stopped using oral 
contraceptives more than 10 years ago do not appear to have any 
increased breast cancer risk. When considering using oral contraceptives, 
women should discuss their other risk factors for breast cancer with their 
health care team (Brinton, et al. 1995). 
 
Alcohol: use of alcohol is clearly linked to a slightly increased risk of 
developing breast cancer. Compared with nondrinkers, women who 
consume 1 alcoholic drink a day have a very small increase in risk, and 
those who have 2 to 5 drinks daily have about 1½ times the risk of 
women who drink no alcohol. Alcohol is also known to increase the risk 
of developing cancers of the mouth, throat, and esophagus (Ferraroni, 
1998). 
 
Not having children: women who have had no children or who had their 
first child after age 30 have a slightly higher breast cancer risk (Kelsey 
and Horn-Ross, 1993). 
 
Hormone replacement therapy: it has become clear that long-term use 
(several years or more) of hormone replacement therapy (HRT) after 
menopause, particularly estrogens and progesterone combined increase 
your risk of breast cancer. Moreover it may also be that they increase 
your chances of dying of breast cancer (Colditz, et al. 1995). 
  
          If the females are still have the uterus, doctors generally prescribe 
estrogen and progesterone (known as combined HRT). Estrogen relieves 
menopausal symptoms and prevents osteoporosis. But estrogen can 
increase the risk of developing cancer of the uterus. Progesterone is added 
to prevent this. If the females are no longer having the uterus, then only 
estrogen is prescribed, this is commonly known as estrogen replacement 
therapy (ERT).  
 
Obesity and high-fat diets: obesity is associated with an increased risk of 
developing breast cancer, especially for women after menopause (which 
usually occurs at age 50). Although ovaries produce most of estrogen, fat 
tissue can change some other hormones into estrogen. Having more fat 
tissue can increase your estrogen levels and increase your likelihood of 
developing breast cancer (Bergstrom, et al. 2001)  
 
 
1.3.5 Factors reducing breast cancer incidence 
          Physical activity: exercise and cancer is a relatively new area of 
research. Recent studies show that strenuous exercise in your youth might 
provide life-long protection against breast cancer and that moderate to 
strenuous physical activity as an adult can lower breast cancer risk. More 
research is being done to confirm these findings (Albanes, et al. 1989).     
 
          Breast feeding: Some studies suggest that breast feeding may 
slightly lower breast cancer risk, especially if breast feeding is continued 
for 1.5 to 2 years. Other studies found no impact on breast cancer risk 
(Furberg, et al. 1999). 
          The explanation of this may be that both pregnancy and breast 
feeding reduce a woman’s total number of lifetime menstrual cycles. This 
  
may be similar to the reduction of risk due to late menarche (start of 
menstrual periods) or early menopause, which also decrease the total 
number of menstrual cycles. One study concluded that having more 
children and breast feeding longer could reduce the risk of breast cancer 
by half (Furberg, et al. 1999).   
 
1.4 Tumor markers 
          Tumor markers are substances that can often be detected in a higher 
than normal amounts in the blood, urine or body tissues in some patients 
with certain type of cancer. Tumor markers are produced either by the 
tumor itself or by the body in response to the presence of cancer or 
certain benign conditions (noncancerous) (Daugaard, 2001).   
          Tumor markers can be used for screening a healthy population or a 
population at high risk for the presence of cancer; making a diagnosis of 
cancer or a specific type of cancer; determining the prognosis in a patient; 
and for monitoring the course in a patient in remission or while receiving 
surgery, radiation, or chemotherapy (Lindblom, 2000).  
  
1.4.1 Carcinoembryonic antigen (CEA) 
          Carcinoembryonic antigen (CEA), an oncofetal glycoprotein, it is a 
glycoprotein of approximately 180-200 k D, that is associated with the 
plasma membrane of tumor cells, from which it may be released into the 
blood, it is expressed in normal mucosal cells and over-expressed in 
adenocarcinoma, especially colorectal cancer. CEA elevations also occur 
with other malignancies such as breast and lung cancer. Non-neoplastic 
conditions associated with elevated CEA levels include cigarette 
smoking, peptic ulcer disease, inflammatory bowel disease, pancreatitis, 
hypothyroidism, biliary obstruction, and cirrhosis. Levels exceeding 10 
ng per mL are rarely due to benign disease (Fletcher, 1996).  
  
 
1.4.2 Cancer antigen of breast cancer (CA 15.3) 
          CA 15.3 is a mucinous antigen defined by 2 monoclonal antibodies. 
These have been raised against human milk fat globule membranes (115 
D8) and metastatic breast cancer cells (DF3) respectively. The antigen is 
an epitope of Polymorphic Epithelial Mucin (PEM), a high molecular 
weight (300-400 K D), heavily glycosylated protein encoded by the 
MUC1 gene. Depending on the tissue the level of glycosylation, and 
therefore, the molecular weight, can vary considerably. While CA 15-3 is 
a normal product of breast cells, in cancer it is frequently over-expressed 
and also spread more widely on the cell membrane rather than restricted 
to the apical surface. Additionally altered glycosylation may expose 
additional epitopes for recognition (Pamies, et al. 1996). 
 
1.4.3 Comparison between CEA and CA15.3 
          CEA is one of the first tumor markers to be identified and 
characterized (Sikorska, et al. 1988). CEA has been evaluated in a wide 
range of malignancies, including breast cancer. Several studies have 
reported that positive serum CEA levels at the time of primary breast 
cancer diagnosis may represent a negative prognostic parameter (Gaglia, 
et al. 1988) and correlate with the stage of disease (Pavesi, et al. 1994). 
Several authors have shown that an increase or a decrease in the CEA 
levels may reflect the status of disease progression or regression (Mughal, 
et al. 1983). CEA may be useful in the postsurgical follow-up of breast 
cancer patients for an early diagnosis of recurrence (Robertson, et al. 
1999). The availability of the CA 15.3 tumor marker in the last decade 
has greatly reduced the value of CEA in breast cancer management, and 
recent studies discouraged the routine use of the CEA assay because of its 
low sensitivity in both early and advanced diseases compared with CA 
  
15.3.  Nevertheless, CEA is still a widely used test for monitoring breast 
cancer patients (Van Dalen, et al. 1996). 
 
1.5 Estrogen 
          Estrogen (17 β – E 2) is a female sex hormone required for the 
growth and function of breast cells. Estrogen E2 - also called estradiol- is 
one of three naturally occurring estrogens (estrone E1, estradiol E2 and 
estriol E3) and is the most potent of the three estrogens in inducing 
estrogen effect. It is important for normal sexual development and is 
essential for the normal functioning of the female organs needed for 
childbearing such as the ovaries and uterus. Estrogen helps to control a 
woman's menstrual cycle. It is important for the normal development of 
the breast. It also helps to maintain healthy bones and the heart. All of 
these are estrogen target tissues-organs or tissues that estrogen can 
influence (Massaro, et al. 2004). During the childbearing years from 
puberty to menopause, organs called the ovaries produce estrogen. After 
menopause, when the ovaries no longer make estrogen, body fat is the 
primary source for estrogen that is made by the body (Lupulescu, 1995).  
The main beneficial effects of estrogen include its role in:  
- Programming the breast and uterus for sexual reproduction.  
- Safeguarding the heart by controlling cholesterol production in ways 
that limit the buildup of plaque in the coronary arteries. 
- Preserving bone strength by helping to maintain the proper balance 
between bone buildup and breakdown.  
          17 β – E 2 is the major estrogenic steroid with a molecular weight 
of approximately 272, which is secreted by the ovaries. The primary 
function of E2 is to prepare the uterine mucosa for the presentational 
stage. It also suppresses the production of FSH and stimulates 
preovulatory LH release from the pituitary. E2 concentration is frequently 
  
useful in evaluating a variety of menstrual dysfunctions, estrogen 
producing tumors, feminization in children and cirrhosis. E2 
concentration is an essential parameter in the monitoring of the induction 
of ovulation and ovarian hyper stimulation. In males, E2 level in serum is 
low. Abnormal levels may be indicative of testicular tumors (Pan, 1994).  
 
 
 
1.5.1 Estrogen and breast Cancer 
          In breast tissue estrogen triggers the proliferation of cells lining the 
milk glands, thereby, preparing the breast to produce milk if the woman 
should become pregnant. 
          In addition to these important beneficial effects of estrogen that are 
mentioned above, it can also be harmful. The most serious problem arises 
from the ability of estrogen to promote the proliferation of cells in the 
breast and uterus (Lupulescu, 1995). Although this ability to stimulate 
cell proliferation is one of estrogen's normal roles, it can also increase a 
woman's chance of developing breast or uterine cancer. 
          During each menstrual cycle, estrogen normally triggers the 
proliferation of cells that form the inner lining of the milk glands in the 
breast. If pregnancy does not occur, estrogen levels fall dramatically at 
the end of each monthly menstrual cycle. In the absence of high estrogen 
levels, those milk gland cells that have proliferated in any given month 
will deteriorate and die, followed by a similar cycle of cell proliferation 
and cell death the following month (Elks, 1993). 
          When cells acquire mutations in specific genes that control 
proliferation, such as proto-oncogenes or tumor suppressor genes, these 
changes are copied with each new generation of cells. Later, more 
  
mutations in these altered cells can lead to uncontrolled proliferation and 
the onset of cancer (Rosen, 2005). 
          Although estrogen does stimulate cell proliferation, therefore, if 
one or more breast cells already possesses a DNA mutation that increases 
the risk of developing cancer, these cells will proliferate (along with 
normal breast cells) in response to estrogen stimulation. The result will be 
an increase in the total number of mutant cells, any of which might 
thereafter, acquire the additional mutations that lead to uncontrolled 
proliferation and that lead to cancer (Murphy, 1997).  
          In other words, estrogen-induced cell production leads to an 
increase in the total number of mutant cells that exist. These cells are at 
increased risk of becoming cancerous, so the chances that cancer may 
actually develop are increased.                                                                                                
          Even in women who do not have any mutant breast cells, estrogen-
induced proliferation of normal breast cells may still increase the risk of 
developing cancer. A cell must duplicate its DNA molecules prior to each 
cell division, thereby ensuring that the two new cells resulting from the 
process of cell division each receive one complete set of DNA molecules. 
But the process of DNA duplication occasionally makes mistakes, so the 
resulting DNA copies may contain a mutation. If one of these 
spontaneous mutations occurs in a gene that controls cell growth and 
division, it could lead to the development of cancer (Murphy, 1997). 
  
CHAPTER TWO 
 
MATERIALS AND METHODS 
 
This study was conducted during the period from February 2004 to 
July 2004; all samples were collected from Sudanese females visiting the 
Radio Isotope Center, Khartoum (RICK) with the objective of measuring 
some parameters associated with the development of breast cancer to 
derive conclusions about the feasibility of early determination and to look 
into the involvement of these parameters as risk factors for breast cancer.     
 
2.1-Subjects 
         Ninty Sudanese females their age range from 25-70 years were 
included in this study. These females were divided into two groups, 
patients group and the control group. 
The patients group included sixty Sudanese females suffering from breast 
cancer visiting the Radio Isotope Center, Khartoum (RICK). The patients 
were confirmed as CA breast by histopathology. The control group 
included thirty healthy Sudanese females. 
 
2.2 Blood sampling 
          Five ml of venous blood from median cubital vein were obtained 
from all subjects, then serum was separated and stored frozen at (-20 °C) 
until analyzed. 
 
2.3 Biochemical methods 
          The method used to measure serum estrogen (E2) is based on 
radioimmunoassay (RIA) technique, while carcinoembryonic antigen 
(CEA) and cancer antigen of breast (CA 15.3) were measured using 
immunoradiometric assay (IRMA).     
  
2.3.1 Principles of radioimmunoassay (RIA)  
          Radioimmunoassay (RIA) is an ideal example of limited reagents 
method. As it uses antibodies at a critical (limited) concentration, based 
on the principle that Antigen (Ag) and tracer -labeled antigen- (Ag*) 
compete with a limited amount of antibody (Ab) to form Ag-Ab or Ag*-
Ab complexes.  
Ag + Ab + Ag* → Ab─Ag (complex) + Ab─Ag* (complex) +Ag + Ag*. 
          In this reaction the supernatant Ag and Ag* is separated from the 
complex Ab─Ag + Ab─Ag*, and the activity of this complex is counted 
using gamma counter. Quantification is made by comparison to known 
analyte standards set up under identical reaction conditions (Chapman, 
1996). 
 
2.3.2 Principles of Immunoradiometric assays (IRMA) 
          Antibody (Ab) in a solid phase reacts with (Ag); the complex that 
formed is washed with washing buffer. The tracer–labeled antibody 
(Ab*) is then added to the complex to form sandwich complex. The 
supernatant Ag and Ab* is separated from the complex Ab─Ag─ Ab* 
and then the gamma counter is used to count the activity. 
Ag + Ab + Ab* → Ab─Ag─ Ab* (complex) + Ag + Ab*. 
 
2.4 Estrogen determination  
          This procedure for the direct determination of serum estrogen is 
based on competitive binding principle of RIA. Standards and patient 
samples are preincubated with estrogen antibody. 125I-E2 then competes 
with estrogen in the standards and the patient samples for a fixed and 
limited number of estrogen antibody sites. After incubation, separation of 
bound from free is achieved by the precipitate (PR) method. The antibody 
  
bound fraction is precipitated and counted. Patient sample concentrations 
are read from a calibration curve (Ccuilleronc and Forestm, 1990). 
 
2.4.1 Reagents 
- 125I-E2 derivative solution (10ml, red, tracer). 
- E2 antiserum solution (10 ml, blue). 
- Seven vials of E2 standards, the standards contain respectively 0, 10, 30,  
  100, 300, 1000, and 2000 (pg/ml).  
- precipitating solution (PR). 
 
2.4.2 Assay procedure   
- The tubes were labeled in duplicates: T (total counts), NSB (nonspecific  
   binding), A (maximum binding), B through G. Additional tubes were   
   labeled for samples. 
- 200 µl of the zero standards A into the NSB and A tubes were pipetted. 
- 200 µl of B through G and samples were pipetted into prelabeled tubes. 
- 100 µl E2 antiserum were dispensed into all tubes except the NSB and T   
   tubes. 
- All tubes were mixed using vortex mixer and incubated for 2 h at room   
  temp. (18-28 °C). 
- 100 µl125I- E2 derivative were dispensed into all tubes, and mixed. 
- All tubes were incubated for 1 h at room temp. (18-28 °C). 
- 500 µl of precipitating solution were added to all tubes (except the T  
  tube), and mixed. 
- Then all tubes were incubated for 10 minutes at room temperature. 
- Centrifugation was done for 20 minutes and the supernatant was  
  discarded, and the activity was read in gamma counter.   
The normal range of females' estrogen is 31- 417 pg/ml. 
 
  
2.5 Carcinoembryonic Antigen (CEA) determination 
          Carcinoembryonic antigen (CEA) was measured using the 
Immunoradiometric assay (IRMA).    
          The CEA assay is a two-side (sandwich) assay in which two mouse 
monoclonal antibodies, directed against two different epitopes of the 
molecules, are employed. Samples or standard are incubated in tubes 
coated with first monoclonal antibody, in the presence of the second 125I 
labeled monoclonal antibody. After the incubation, the liquid content of 
the tubes are aspirated and the excess of unbound labeled antibody is 
removed by washing. The bound radioactivity measured in gamma 
counter is proportional to the CEA concentration. Unknown values of the 
samples to be assayed are determined by interpolation from the standard 
curve (Bormer, 1991; Nap, et al. 1992).  
 
2.5.1 Materials provided 
- 1 vial 125 I-labeled CEA, red, lyophilized. 
- 5 vials CEA standards, lyophilized. Nominal values are as follows: 
  5, 10, 20, 40,80 ng/ml.   
- 1 vial CEA antibody, blue lyophilized. 
- 1 vial precipitation solution. 
- 1 vial incubation solution. 
 
2.5.2 Reagents preparation 
- 11 ml incubation solution was added to 125 I-labeled CEA. 
- 1 ml incubation solution was added to each vial of CEA standard. 
- 11 ml incubation solution was added to CEA antibody. 
 
2.5.3 Procedure  
- The tubes were labeled in duplicates: T (total counts), NSB (nonspecific  
   binding), A (maximum binding), B through F. Additional tubes was 
  
   labeled for samples. 
- 100 µl of incubation solution were added into the appropriate tubes. 
- 100 µl of standards and samples were added in the specific tubes. 
- 100 µl of antibody were added into the appropriate tubes. 
- All the tubes were mixed gently and incubated at 37 °C for two hrs. 
- 100 µl of  125 I-CEA were added into each tube. 
- All the tubes were mixed gently and incubated at 37 °C for two hrs. 
- 500 µl precipitant solutions were added into each tube except T tube. 
- All tubes were mixed and incubated at room temperature for half an  
  hour. 
- All tubes were centrifuged for 20min. 
- The supernatant was discarded. 
- The remaining activity of all tubes were counted using gamma counter. 
The normal value of carcinoembryonic antigen is below 10ng/ml                                         
 
2.6 Cancer Antigen of breast CA 15.3 determination  
          Cancer antigen of breast is measured using the Immunoradiometric 
assay (IRMA).    
 
2.6 .1 Reagents preparation  
- 5ml of distilled water were added to redissolve the standard from A 
to E. 
- The concentrations of the standards were A: 11, B: 28, C: 73, D: 
140, 
      E: 230 U/ml. 
- All the samples were diluted 10 times with dilution buffer. 
- The antibody coated tubes were labeled 0 for nonspecific binding 
and A to E for standard in duplicates and for patients samples S1, 
S2, …… Sn. 
  
- Two uncoated tubes were labeled for total counts. 
 
2.6.2 Assay procedure 
- 200 µl of incubation buffer were added into 0 tube and 150µl of            
  incubation buffer into all other tubes except T tube. 
- 50 µl of standard and diluted sample were added to the corresponding   
  tubes. 
- The tubes were mixed gently and incubated for two hours at 37°C. 
- All the solutions of the tubes were aspirated completely. 
- 1ml of distilled water were added to each tube and decanted. This step  
   was repeated again. 
- 200 µl of 125 I anti CA15.3 monoclonal antibody were added to all tubes. 
- The tubes were mixed gently and incubated for three hours at room  
  temperature. 
- The solution of all tubes was aspirate completely and all the tubes were  
   washed twice with 1 ml distilled water except T tube. 
- The activity was count for 1 minute in gamma counter. 
The normal value of cancer antigen of breast is below 40 U/ml. 
 
2.7 Equipments used 
1- Syringe, Germany5ml 0.7X30mm/22G X11A. 
2- Storage tubes. 
3- Tubes: polystyrene assay tubes code No.5001, round bottomed tubes   
     with a capacity of 5ml and Intermediate g.mm, from allied from  
     Amersham International Ltd. Amersham, U.K. 
4- Pipettes (25-1000µl) and disposable tips from eppendorf Gmbt,  
    Itamurage 65, Fed, Re p. Gsermany. 
5- Adjustable repeating syringe (50 µl - 2ml per shot) and comb tips from   
    eppendorf Gmbt, Itamurage 65, Fed, Re p .Germany. 
  
6- Vortex mixture, model G560-E from scientific industries ink Bohemia    
    N.Y11716, USA. 
7- Incubator. 
8-.Refrigerated bench top centrifuge model Centra-7R, from International  
    equipment company, 300 second Avenue, need hard high TS, AM,  
    02194, USA 
9- Multi detector gamma counter NE 1612 from nuclear enterprises Ltd.  
    Sight hill Edinburgh, UK. 
 
2.8 Statistical analysis 
          Statistical analysis was performed using the software Statistical 
Package for Social Sciences (SPSS) including data evaluation and tests for 
significance.  Graph plots were done via windows excel version.    
 
 
 
  
CHAPTER THREE 
 
RESULTS AND DISCUSSION  
 
          Ninty subjects were included in this study divided into two groups, 
patients group (sixty) and control group (thirty) their ages range from 25-
70 years. The patients group was confirmed as CA breast by 
histopathology.  
          For all subjects, the serum levels of estrogen E2, carcinoembryonic 
antigen CEA and cancer antigen of breast cancer CA 15.3 were measured 
using radioimmunoassay technique. 
 
3.1 Estrogen concentrations 
          The level of estrogen in the patients group and control is presented 
in table (1) and Fig. (2). E2 concentrations (pg/ml) measured in this study 
for the control and patients group were within the normal range. 
Therefore, no significant (p = 0.05) difference in the serum levels of 
estrogen was detected between the control subjects and the breast cancer 
patients. 
          Estrogen plays an important role in breast cancer (Colditz, 1998). 
Our data showed that no difference between the control and the patients 
with breast cancer concerning estrogen level. These findings agree with 
the works of Jones, et al. (1987); Reed, et al. (1983); Helzlsouer, et al. 
(1994); Sturgeon, et al. (2004) who found that no convincing or 
consistent difference between normal women and women with breast 
cancer concerning estrogen level. 
          Although some studies agree with our results, there were some 
studies which found good associations between the serum levels of 
estrogen and breast cancer.  Toniolo, et al. (1995); Hankinson, et al. 
  
(1998) and Missmer, et al. (2004) reported that a positive association 
between breast cancer and the level of estrogen.  
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table (1): The levels of estrogen, carcinoembryonic antigen and 
cancer antigen of breast cancer in breast cancer patients   
                                            and control subjects   
 
 
E2 (pg/ml) 
Mean ± SD 
CEA (ng/ml) 
Mean ± SD 
CA 15.3 (U/ml) 
Mean ± SD 
 
control 
Breast caner 
patients 
 
control 
Breast caner 
patients 
 
control 
Breast cancer 
patients 
 
121.10±84.15402a 
 
116.65±127.1558a 
 
 
28.4±41.22914a 
 
 
44.50±76.59674a 
 
 
16.30±6.78349a 
 
 
59.16±78.4194b 
 
 
Means within the same raw having different superscript letters are 
significantly different at (p<0.0001). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig. (2): Estrogen levels in patients with breast cancer and  
                                control subjects 
 
 
0
20
40
60
80
100
120
140
control group  patients group
E
st
ro
ge
n 
(p
g/
m
l)
 
 
 
 
  
3.2 CEA concentrations 
          As shown in table (1) and Fig. (3), the CEA mean values were non- 
significantly (p>0.05) higher in patients group compared to the control 
group.  
          These results agree with Saccani, et al. (1988) and Helier, et al. 
(1990) who found that no significant difference between the patients with 
breast cancer and the control. 
Incontrast to our results, Hayes, et al. (1986) and Norum, et al. 
(2001) found a significant elevation in the serum levels of CEA in 
patients with breast cancer than in the control.   
 CEA as a tumor marker is not a very precise tool for breast cancer 
diagnosis when it is used alone, especially for early breast cancer. 
Therefore, by combining it with another tumor marker such as CA 15.3, 
the efficiency of CEA can be improved (Omar, et al. 1988). 
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Fig. (3): Carcinoembryonic antigen levels in patients with breast cancer and 
 
control subjects 
  
3.3 CA 15.3 concentrations 
          CA 15.3 concentrations were presented in table (1) and Fig. (4). 
The level of CA 15.3 is highly significant (p < 0.0001) in the patients 
with breast caner compared to the control.  
          This result is in agreement with the Hayes, et al. (1986) and Gion, 
et al. (1991) who reported a highly significant difference between the 
patients suffering from breast cancer and the control. 
          The result obtained in our study confirmed that CA 15.3 is a 
sensitive tumor marker for the evaluation and monitoring of patients with 
breast cancer (Hayes, et al. 1986).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
control group  patients group
C
A
 15
.3
 (U
/m
l)
 
 
 
 
 
Fig. (4): Cancer antigen of breast levels in patients with breast cancer and 
 
control subjects 
  
3.4 Conclusions and Recommendations           
         It is concluded from this study that the level of CA 15.3 could be 
used for the early detection and diagnosis of breast cancer. Since it was 
significantly increased in the patients of breast cancer compared to the 
control. 
          More investigation is needed in this area, such as the relation 
between breast cancer and free estradiol, some hormones such as 
prolactin and progesterone. It is preferable that the measurement of the 
serum levels of hormones is supported by the measurement of the 
receptors so that the finding will be more reliable.   
  
 
REFERENCES 
 
 
Albanes, D., Blair, A. A., Taylor, P. R. (1989). Physical activity and risk 
of cancer in the NHANESI population. Am. J. Public. Health. 79:744-
750. 
Andrew, M. and Tim, H. (1993). The Cell Cycle an introduction, Oxford 
University Press.7-8. 
Bergstrom, A., Pisani, P., Tenet, V., Wolk, A., Adami, H-O. (2001). 
Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer. 
91:421-430.  
Bormer, O. P. (1991). standardization, specificity, and diagnostic 
sensitivity of four immunoassays for carcinoembryonic antigen. Clin. 
Chem. 37 (2):231-236. 
Brinton, L. A., Daling, J. R., Liff, J. M. (1995). Oral contraceptives and 
breast cancer risk among younger women. J. Natl. Cancer Inst. 
87:827-35. 
Calle, E. E., Mervis, C. A., Thun, M. J., Rodriguez, C., Wingo, P. A., 
Healthy, C. W. (1996). Diethylstilbestrol and risk of fatal breast 
cancer in a prospective cohort of US women.. Am. J. Epidemiol. 144 
(7):645-51. 
Ccuilleronc, Y., Forestm. (1990). Nucl. Med. Biol. 17:661.     
Chapman, J. D.  (1996). Immunoassays for clinical chemistry, 125I-2nd 
edition, Churchil Livingstone. 178-190.  
Colditz, G. A. (1998). Relationship between estrogen levels, use of 
hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 
90:814-23. 
  
Colditz, G. A., Hankinson, S. E., Hunter, D. J. (1995). The use of 
estrogens and progestins and the risk of breast cancer in 
postmenopausal women. N. Engl. J. Med. 332:1589-1593. 
Colditz, G. A., Rosner, B. A., Speizer, F. E. (1996). Risk factors for 
breast cancer according to family history of breast cancer. For the 
Nurses’ Health Study Research Group. J. Natl. Cancer Inst. 88: 365–
371. 
Daugaard, G. (2001). The clinical use of tumor markers in germ cell 
cancer. J. of Tumor Marker Oncol. 16: (1).  
Elks, M. L. (1993). Peripheral effects of steroid hormones, implications 
for patient management, J. Am. Med. Women Assoc. 48:41-55. 
Eskelinen, M., Tikanoja, S., Valkamo, E., Loikkanen, M., Collan, Y. 
(1988). Cancer-associated antigen CA 15-3 in the diagnostics of breast 
tumors. Scand J. Clin. Lab. Invest. 48 (7):653-8. 
Ferraroni, M., Decarli, A., Franceschi, S., La Vecchia, C. (1998). Alcohol 
consumption and risk of breast cancer: a multi Italian case-control 
study. Eur. J. Cancer; 34:1403–1409. 
Fletcher, R. H. (1996). Carcinoembryonic antigen. Ann. Intern. Med., 
104: 66-73.  
Furberg, H., Newman, B., Moorman, P., Millikan, R. (1999). Lactation 
and breast cancer risk.. Int. J. Epidemiol. 28:396–402. 
Gaglia, P., Caldarola, B., Bussone, R., Potente, F., Lauro, D., Jayme, A., 
Caldarola, L. (1988). Prognostic value of CEA and ferritin assay in 
breast cancer: a multivariate analysis. Eur. J. Cancer Clin. Oncol., 
24:1151-1155.  
 Gary, S. S., Arthur, B. P. (2004). Cell cycle and growth control, Wiley-
IEEE Publishers, London. 
Gion, M., Mione, R., Nascimben, O., Valsecchi, M., Gatti, C., Leon, A., 
Bruscagnin, G. (1991). The tumor associated antigen CA15.3 in 
  
primary breast cancer. Evaluation of 667 cases. Br. J. Cancer. 63 
(5):809-13.  
Hankinson, S. E., Willett, W. C., Manson, J. E., Colditz, G. A., Hunter, 
D. J., Spiegelman, D. (1998). Plasma sex steroid hormone levels and 
risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 
90:1292-9. 
Hayes, D. F., Zurawski, V. R. Jr Kufe, D. W.  (1986). Comparison of 
circulating CA15-3 and carcinoembryonic antigen levels in patients 
with breast cancer. J. clin. Oncol. 4:1542-1550. 
Helier, R., Fisher, R., Nash, A., Knapp, J. (1990). Lack of relationship 
between parity and level of carcinoembryonic antigen in women with 
breast cancer. Anticancer Res. 10 (6):1755-1757. 
Helzlsouer, K. J., Alberg, A. J., Bush, T. L., Longcope, C., Gordon, G. 
B., Comstock, G. W. (1994). A prospective study of endogenous 
hormones and breast cancer. Cancer Detec.t Prev. 18:79-85. 
John, E. M. and Kelsey, J. L. (1993). Radiation and other environmental 
exposures and breast cancer, Epidemiol. Rev. 15:157–162. 
Jones, L. A., Ota, D. M., Jackson, G. A., Jackson, P. M., Kemp, K., 
Anderson, D. E., Mc Camant, S. K., Bauman, D. H. (1987). 
Bioavailability of estradiol as a marker for breast cancer risk 
assessment. Cancer Res. 47(19):5224-9. 
Kelsey, J. L., and Horn-Ross P. L. (1993). Breast cancer magnitude of the 
problem and descriptive epidemiology. Epidemiol. Rev. 5:7–16. 
Key, T. J., Verkasalo, P. K., Banks, E. (2001). Epidemiology of breast 
cancer. Lancet. Oncol. 2 (3):133-40. 
Lindblom, Annika, and Annelie Liljegren. (2000). Tumor markers in 
malignancies. Brit.  Med.  J. 320:424. 
Lupulescu, A. (1995). Estrogen use and cancer incidence: a review. 
Cancer Invest. 13:287-295. 
  
Massaro, D., Massaro, G., D. (2004). Estrogen regulates pulmonary 
alveolar formation, loss and regeneration in mice. Lung cellular and 
molecular physiology. Amer. J. of physiol. 287 (6):1154-1159.  
Missmer, S. A., Eliassen, A. H., Barbieri, R. L., Hankinson, S. E. (2004).  
Endogenous estrogen, androgen, and progesterone concentrations and 
breast cancer risk among postmenopausal women. J. Natl. Cancer 
Inst. 96:1856-1865. 
Morris, E. A., Liberman, L., Ballon, D. J., Robson, M., Abramson, A. F., 
Heerdt, A., Dershaw, D. D. (2003). MRI of occult breast carcinoma in 
a high-risk population. Am. J. Roentgenol. 181:619-626. 
Mughal, A. W., Hortobagyi, G. N., Fritsche, H. A., Buzdar, A. U., Yap, 
H. Y., Blumenschein, G. R. (1983). Serial plasma carcinoembryonic 
antigen measurements during treatment of metastatic breast cancer. J. 
Am. Med. Assoc. 249:1881-1886.  
Murphy, G. P. (1997). The american cancer society's informed decisions, 
The complete book of cancer diagnosis, treatment, and recovery by 
New York: penguin books USA, 689.  
Nap, M., Hammerstorm, M. L., Bormer, O., Hammerstorm, S., Wagner, 
C. H., Handt, S., Schreyer, M., Mash, J. P., Buschegger, F.,  Kleist 
von, S., Grunert, F., Seguin, P. (1992). Specificity, and affinity of 
monoclonal antibodies against carcinoembryonic antigen. Cancer 
Resesrch. 52:2329-2339.   
National Academy of Sciences. (2005). Saving women's lives, National 
academy press.  
Nicola, G., Smee, Victor, G., Vogel, Therese Bevers. (2003). Handbook 
of breast cancer risk-assessment. Jones and Bratlett Publishers. 
Norum, L. F., Erikstein, B., Nustad, K. (2001). Elevated CA125 in breast 
cancer--A sign of advanced disease. Central Laboratory, Norwegian 
Radium Hospital, Oslo, Norway. Tumour Biol. 22 (4):223-8. 
  
Omer, Y. T., Behbehani, A. E., Al Naqueeb, N. (1988). 
Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in 
preoperative staging and postoperative monitoring of patients with 
carcinoma of the breast. Int. J. Biol. Markers, 3 (3):165-171. 
Pamies, R. J., Deborah, R., C. (1996). Tumor markers, an update. Med. 
Clin. North  America. 185-99.  
Pan, zhong yun, (1994). Clin.  Nuclear Med. 461-463.   
Pavesi, F., Lotzniker, M., Scarabelli, M., Mauro, E., Visconti, G., 
Nicolato, E., Moratti, R. (1994). Circulating CA549 and other 
associated antigens in breast cancer patients. Oncol. 51:18-21.  
Philip, C., Harris, P. (2001). Fundamentals of cancer epidemiology. Jones 
and Bartlett Publishers, 23-25. 
Reed, M. J., Cheng, R. W., Noel, C. T., Dudley, H. A., James, V. H. 
(1983). Plasma levels of estrone, estrone sulfate, and estradiol and the 
percentage of unbound estradiol in postmenopausal women with and 
without breast disease. Cancer Res. 43 (8):3940-3. 
Robertson, J. F., Jaeger, W., Syzmendera, J. J., Selby, C., Coleman, R., 
Howell, A., Winstanley, J., Jonssen, P. E., Bombardieri, E., Sainsbury, 
J. R., Gronberg, H., Kumpulainen, E., Blamey, R. W. (1999). The 
objective measurement of remission and progression in metastatic 
breast cancer by use of serum tumour markers. European group for 
serum tumour markers in breast cancer. Eur. J. Cancer. 35:47-53. 
Rosen, E. M., Fan, S., Isaacs, C. (2005). BRCA1 in hormonal 
carcinogenesis basic and clinical research. Endocrine-Related Cancer. 
12:533-548.  
Rosner, B, Colditz, G. A. (1996). Nurses’ health study, log-incidence 
mathematical model of breast cancer incidence. J. Nat. Cancer Inst. 
88:359-64. 
  
Saccani, J. G., Bombardieri, E., Fontanesi, M., Becchi, G., Bocchi, P., 
Palli, D., Rusca, M., Rusconi, A., Pizzorno, B., Tardini, A. (1988). 
Plasma and tissue CEA and TPA markers in operable breast cancer. 
Tumor. 31;74 (6):681-8.    
Sikorska, H., Shuster, J., Gold, P. (1988). Clinical applications of 
carcinoembryonic antigen. Cancer Detect. Prev. 12:321-355.  
Singletary, S. E., Allred, C., Ashley, P. (2002). Revision of the American 
joint committee on cancer staging system for breast cancer. J. Clin. 
Oncol. 17:3628-36.  
 Stern, K. and McClintock, M. K. (1998). Regulation of ovulation by 
human pheromones.  Nature, 392:177–179. 
Sturgeon, S. R., Potischman, N., Malone, K. E., Dorgan, J. F., Daling, J., 
Schairer, C., Brinton, L. A. (2004) Serum levels of sex hormones and 
breast cancer risk in premenopausal women: a case-control study 
(USA). Cancer Causes Control. 15 (1):45-53. 
Susan, G. K. (2005). The health communication research laboratory at 
Saint Louis University. Breast cancer foundation.      
Tonin, P. N. (2000). Genes implicated in hereditary breast cancer 
syndrome, Semin. Surg. Oncol. 18:281–286. 
Toniolo, P. G., Levitz, M., Zeleniuch-Jacquotte, A., Banerjee, S., Koenig, 
K. L., Shore, R. E. (1995). A prospective study of endogenous 
estrogens and breast cancer in postmenopausal women. J. Natl. 
Cancer Inst. 87:190-7. 
US mortility public use datatape 2002. (2004). National center for health 
statistics, center for disease control and prevention.  
Van Dalen, A., Heering, K. J., Barak, V., Peretz, T., Cremaschi, A., 
Geroni, P. (1996). Treatment response in metastatic breast cancer. A 
multicentre study comparing UICC criteria and tumour marker 
changes. Breast. 5: 82-88. 
  
 
 
